Study Group: Pathologists (US)
Council Members in this Study Group: 792
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Robert Boorstein
Associate Professor, Pathology
NEW YORK UNIVERSITY (INC)
Robert Boorstein, MD, PhD, is an Associate Professor in the Department of Pathology at New York University School of Medicine, where he directs clinical pathology training. Previously, Dr. Boorstein was the Director of Pathology at Bellevue Hospital and...
- John Cochran
Founder and Senior Pathologist
Chestatee Pathology Associates, PCJohn Cochran, MD, is the Founder and the Chief Executive Officer of Chestatee Pathology Associates in Atlanta, GA. He is also the Medical Director of two Atlanta-area hospital laboratories and founded the first independent podiatric pathology laboratory...
- Jed Gorlin
Transfusion Service Director
HENNEPIN HEALTHCARE SYSTEM INCJed Gorlin, MD, MBA, is the Medical Director of the Memorial Blood Center of Minnesota and an Associate Professor of Laboratory Medicine and Pediatrics at the University of Minnesota. Dr. Gorlin is also the Transfusion Services Director at Hennepin County...
- Joseph Schappert
Medical Director
PROVIDENCE HEALTH CAREJoseph Schappert, MD, is the Chief Medical Officer at Pathology Associates Medical Laboratories (PAML) and the Medical Director for Providence Health Care System. He was previously the Global Medical Director at ICON Central Laboratories, where he was...
- Jin Suh
Assistant Clinical Professor of Medicine
NEW YORK PRESBYTERIAN & COLUMBIA MEDICAL CENTERJin Suh, MD, is an Assistant Clinical Professor of Medicine at the Columbia University College of Physicians and Surgeons. He is also an Associate Medical Director of the HIV-AIDS Program at St. Luke's-Roosevelt Hospital, New York. Dr. Suh is board certified...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
What is potential future for Sequenom in prenatal testing.
November 9, 2009
So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com
The historic but minimally supported enthusiasm for the Sequenom prenatal test has previously been reported in this space previously. Even in the absence of data retractions, leading to termination of much of senior management, problems in the rollout of the product should have been anticipated.Remarkably, this article asserts that industry insiders remain optimistic about the development of a successful diagnostic product.
-
Potential impact of large clinical trial on Liquid based cytology market
November 5, 2009
Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com
The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology has essentially replaced conventional Pat testing in this country, and it is unlikely that there is evidence that would reverse this. However, it is possible such studies will put downward pricing pressures on reimbursments, both in amounts and frequencies.
-
New entrant to DTC genetic testing market raises regulatory and financial questions
July 16, 2009
New DTC Genetics Firm Pathway Genomics Launches | www.genomeweb.com
Pathway Genomics is the latest entrant into the DTC genetic testing market. They offer an extensive amount of genetic information (over 90 individual results) at a price point of $250. This undercuts both existing DTC providers, like 23andme, decode genetics, etc., but also appropriately licensed genetics providers. These companies seem to be threading the needle between providing a service for "research and education only", with extensive legal disclamers, and providing useful information and interpretations which affect medical decisions. Sooner or later, governmental agencies have to make a decision on whether to clearly subject these companies to explicit regulatory scrutiny, both at the federal and state level. Notwithstanding, this company would seem poised f
-
Analyst upgrades of Genomic Health: Lagging or leading indicator
June 12, 2009
Analyst Upgrades Genomic Health | www.genomeweb.com
Genomic Health is a molecular diagnostic company with one major product on the market and others potentially in the pipeline. Wall street has had only modest coverage of this company and generally assessments have been neutral. In assessing this company, it is important to recognize that it has some unique positive features in its business model, as well as some downside risks of potentially great magnitude.
-
Jumping off the Bandwagon: Decline in Sequenom shares takes world by surprise
May 1, 2009
UPDATE 2-Sequenom delays Down Syndrome test; shares plunge | uk.reuters.com
The market cap of Sequenom has been bid up to the $billion US level by the potential of a single product. Many in the investment community have been following this closely. Overwhelmingly, investor sentiment has been bullish, both among the professional investment community, and in the public measures of sentiment (i.e, the motley fool). Recently, the rug has been pulled out from this company by an announcement that it was delaying the launch of its test for Down's syndrome. The collapse of the stock, however, should not come as a surprise. Numerous warning signs were clearly apparent to onlookers familiar with the processes by which new tests become standards of care. Many of these issues were raised previously in this forum. https://news.glgroup.com/cm/Analysis/PostDetail.aspx?pid=35151
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Academic Institution*
- Lab, Academic Medical Center
- Laboratory, Independent
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Director
- Professor
- Physician - Director
- Research Scientist
- Physician - Department Chair
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Cytopathologists (US) | 66 |
| Infectious Diseases Physicians (US) | 885 |
| Oncologists (US) | 2241 |
| Blood Banking and Transfusion Medicine Pathologists (US) | 35 |
| Digene-HPV DNA Panel Users: Pathologists (US) | 29 |
| Hematologists (US) | 994 |
| Users of Automated Slide Strainer (US) | 37 |
| Forensic Pathologists (US) | 18 |